Patient treatment satisfaction after switching to NovoMix® 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors
| Autor: | Paul Valensi, Joseph Shaban, Meryl Brod, Torsten Christensen, Don M. Bushnell |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Insulin Isophane Type 2 diabetes Biphasic Insulins NovoMix 30 Article Treatment satisfaction Insulin aspart Young Adult Patient satisfaction Diabetes mellitus Observational study Surveys and Questionnaires medicine Humans Hypoglycemic Agents Insulin Child Insulin Aspart Aged Aged 80 and over Clinical Trials as Topic business.industry Public Health Environmental and Occupational Health Middle Aged medicine.disease Hypoglycemia Surgery Diabetes Mellitus Type 2 Patient Satisfaction Physical therapy Treatment factors Female business medicine.drug |
| Zdroj: | Quality of Life Research |
| ISSN: | 0962-9343 |
| DOI: | 10.1007/s11136-010-9699-0 |
| Popis: | Purpose Understanding treatment satisfaction (TS) for diabetes is increasingly important as treatment options increase. This study examines treatment satisfaction with NovoMix® 30 in an observational study in patients with type 2 diabetes. Methods The DiabMedSat assesses Overall, Treatment Burden, Symptom and Efficacy Treatment Satisfaction. The impact of type of pretreatment variables on TS was examined by ANOVA at baseline and week 26. Satisfaction at week 26 was examined by t-test and effect size. Linear regression models examined impact of prior treatment factors (age, gender, duration of diabetes, type of prior treatment and diabetes-related comorbidities) and current treatment factors (weight gain, hypoglycemic events, reaching therapeutic goal) on TS. Results The data set comprised 17,488 persons. Prior treatment with insulin had a more positive impact on baseline satisfaction. At week 26, there were no differences between type of prior treatment groups in Overall, Symptoms and Burden TS. Current treatment with NovoMix 30 significantly improved TS. Regression analyses examining the combined effect of pretreatment factors and current treatment factors found that all factors except for age-impacted TS although the domains impacted varied. Conclusions Patients treated with NovoMix 30 reported improved treatment satisfaction, and the improvement is considered clinically meaningful to patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|